Consistently with the reduced binding of IL-2v to CD25, CEA-IL-2v induced a CD8+:CD4+ ratio toward CD8+ T cells both in the periphery and in the tumor associated with single-agent and combination efficacy in syngeneic models. The gene discussed is CD8A; the disease is neoplasm.